Introduction
Amplification or overexpression of the HER2/neu oncogene (also named c-erbB2, abbreviated as HER2) is frequently found in various cancer types, including breast, ovarian, lung, gastric, and oral cancers (Slamon et al., 1987; Hung, 1995) . Also, HER2 overexpression has been associated with shorter survival in cancer patients (Slamon et al., 1987) . Recently, it was shown that HER2 can activate the Akt pathway to decrease p53 stability via mediation of MDM2 phosphorylation (Zhou et al., 2001b) . MDM2 is an ubiquitin E3 ligase involved in p53 degradation. Importantly, in the HER2-Akt pathway, Akt phosphorylates MDM2 at Ser166 and Ser186 to enhance MDM2 nuclear localization, thus causing p53 degradation to decrease cell growth (Zhou et al., 2001b) . Given that alternative reading frame protein (ARF), a negative regulator of cell cycle, interacts with MDM2 and antagonizes MDM2's inhibitory activity (Pomerantz et al., 1998) , it is possible that HER2 signaling disrupts ARF activity toward MDM2 to regulate p53 stability. However, ARF's role in HER2 signaling is not well characterized. Also, we previously showed that HER2 signaling was involved in enhancing ubiquitin-mediated degradation of p27Kip1(p27), a cyclin-dependent kinase (CDK) inhibitor, and causing p27 cytoplasmic localization (Yang et al., 2000b) . Together, these data indicate that HER2 signaling deregulates negative regulators of the cell cycle, including p27 and ARF, and thus gives cells a mitogenic advantage.
The Ink4a/Arf locus has two promoters and encodes two different proteins with alternative splicing: p16 (Ink4a) and ARF (p19ARF in mouse, p14ARF in human) (Quelle et al., 1995) . p16 is a G1 cell cycle inhibitor that binds to cyclin D-CDK4 and -CDK6 complexes and inhibits their kinase activities (Serrano et al., 1993) , whereas ARF associates with MDM2 and modulates MDM2-mediated degradation of p53 and does not bind to any cyclin-CDKs (Zhang et al., 1998; Tao and Levine, 1999; Weber et al., 2000b) . Expression of ARF can be induced by activated cellular or viral oncogenes, including c-Myc , ras (Palmero et al., 1998) , v-Abl (Radfar et al., 1998) , and E1A (de Stanchina et al., 1998) . Upregulation of p19ARF can inhibit the ubiquitin ligase activity of MDM2, thus mediating the accumulation of p53 (Zhang et al., 1998) . Indeed, E1A and c-Myc enhance p53 levels and p53 transcriptional activity, thereby leading to promotion of apoptosis. This is due to ARF-mediated stabilization of p53 because ARF-null cells became resistant to E1A-and c-Myc-induced apoptosis (de Stanchina et al., 1998; Zindy et al., 1998) . Deficiency of ARF or p53 results in the elimination of this tumor surveillance mechanism, allowing oncogenes to promote uncontrolled growth. Significantly, ARF-null mice are prone to tumor development (Kamijo et al., 1997; Kamijo et al., 1999) , highlighting the role of ARF in tumor surveillance. Interestingly, heterozygous ARF knockout mice develop tumors after a longer latency, with tumors accompanied by the loss of the remaining ARF allele, suggesting that ARF acts as a classical tumor suppressor gene (Kamijo et al., 1999) . Indeed, gene deletion of ARF has now emerged as the second most frequent mutation event in tumorigenesis, present in about 40% of cancers overall (Haber, 1997; Vonlanthen et al., 1998) . Overexpression of ARF results in cell cycle arrest and apoptotic cell death in mesothelioma (Yang et al., 2000a) and even in tumor cells without functional p53 and retinoblastoma pathways (Saadatmandi et al., 2002) .
Also, recombinant adenovirus-mediated p14ARF expression greatly increases the sensitivity of breast cancer cells to the chemotherapeutic drug cisplatin (Deng et al., 2002) , suggesting that ARF gene transfer alone or in combination with chemotherapy can be used for the treatment of cancer. While the growth suppressive activity of ARF was related to its ability to stabilize p53, recent data have shown that ARF can also inhibit cell growth in a p53-independent manner (Weber et al., 2000a) . For example, ARF can induce growth inhibition in p53-null cells (Eymin et al., 2001) . In addition, mice with gene disruption for ARF, p53, and Mdm2 (triple knockout) develop multiple tumors more frequently than mice lacking p53 and Mdm2 or p53 alone (Weber et al., 2000a) , indicating that ARF can inhibit tumor development independently of the p53-Mdm2 pathway. So far, the mechanisms involved in p53-independent ARF activity are not well characterized.
Given the important roles of HER2 in tumorigenesis, cancer cells overexpressing HER2 are an excellent target for the anticancer therapies. Little is known about the tumor suppressor role of ARF in HER2-overexpressing cancers. Since HER2 signaling may be involved in deregulating MDM2-ARF activity, enhancing ARF expression may constitute a therapeutic intervention in HER2-associated cancers. Here, we showed that ARF expression stabilized p27 in HER2-overexpressing cells, inhibiting HER2-mediated p27 ubiquitination and degradation. We also examined the effectiveness of using ARF as a therapeutic agent for HER2-overexpressing cells under a gene expression system regulated by tetracycline (Gossen and Bujard, 1992) . We demonstrated that the ARF expression could inhibit HER2-mediated cell proliferation, anchorage-independent growth, and cell transformation. Furthermore, we showed that ARF expression reduced tumorigenicity of HER2-overexpressing cells in nude mice. These results indicate that modulation of ARF activity may be a useful therapeutic intervention in HER2-overexpressing cancers.
Results

p19ARF inhibits cell cycle growth and stabilizes p27 expression
HER2 signaling results in Akt activation and subsequent nuclear localization of MDM2 through Aktmediated MDM2 phosphorylation, thereby positively regulating MDM2 activity (Zhou et al., 2001b) . Since ARF interacts with MDM2 and antagonizes MDM2's inhibitory activity (Pomerantz et al., 1998) , we determined whether HER2 signaling interrupted ARF's activity toward MDM2 using a coimmunoprecipitation assay. Cells were cotransfected with MDM2, Flagtagged p19ARF (p19), and increasing amount of HER2 into 293Tcells. When the amount of HER2 was increased, the phosphorylation level of Akt on Ser473 increased, suggesting that HER2 activity affected Akt's kinase activity (Figure 1a ). Importantly, less MDM2 was detected in the anti-Flag (p19) immunoprecipitated complex under conditions where HER2 is increased, suggesting that HER2 overexpression reduces the interaction between MDM2 and p19ARF ( Figure 1a ). We also found that more p53 was detected in the anti-MDM2 immunoprecipitated complex when HER2 is increased, showing that HER2 overexpression facilitates the interaction between MDM2 and p53 ( Figure 1a ). As expected, HER2 signals lead to downregulation of p53 ( Figure 1a) . Together, these results indicated that HER2 signal reduces the binding between p19 ARF and MDM2 to downregulate p53 protein level, possibly through Akt activation.
Given the link between HER2 signals and ARF regulation, we then determined the biological effects of p19 expression on HER2-overexpressing cells by employing a tet-inducible system (Gossen and Bujard, 1992) . HER2-overexpressing NIH3T3 cells stably express tTA (transcriptional activator) was established by transfecting with pUHD15-1 (neo) vector (Gossen and Bujard, 1992) . We then constructed tet-off regulated p19-expressing cells by transfecting pUHD10-3 hygromycin vector cloned with Flag-tagged p19. We were able to identify several clones, and one representative clone can have induced expression of p19 by adjusting the concentration of tet as detected by immunoblotting with anti-Flag antibody (Figure 1b) .
To assess the p19-mediated antiproliferative effects, we measured and compared the antimitogenic activity of p19-expressing cell lines (Àtet) and control cell lines ( þ tet) by measuring growth rate as determined by MTT assay (Laronga et al., 2000) . The growth rate was dramatically reduced in the p19-expressing cells (NIH3T3/HER2/tTA-p19 in the absence of tet) (Figure 1c ). To investigate further this growth inhibitory activity of p19, we investigated the effect of p19 on cell cycle regulators that are regulated by HER2 signaling, including p27 (Yang et al., 2000b) and cyclin D1 . We found that p27 protein levels were increased, while cyclin D1 levels were diminished in the presence of p19 expression (Figure 1d ). We also found that p19-mediated high-level expression of p27 resulted in the inhibition of CDK2-associated histone H1 kinase activity (Figure 1d ). Since cyclin D1 is a positive regulator participating in HER2 mitogenic growth , we examined the effects of p19 on cyclin D1 expression. We found that p19-mediated downregulation of cyclin D1 resulted from p19's activity in antagonizing HER2-mediated cyclin D1 expression, as demonstrated by the inhibition of cyclin D1 luciferase reporter gene activation (Figure 1e ). Together, these results indicated that p27 and cyclin D1 are two effectors involved in p19-mediated cell cycle inhibition in HER2-overexpressing cells.
To determine whether p19-mediated high-level expression of p27 expression resulted from the increased stability of p27, we determined the protein stability of p27 by cycloheximide treatment in NIH3T3/HER2/ tTA-p19 cells treated with or without tetracycline ( Figure 2a) . We found that the p19-expressing cells (Àtet) exhibited a reduced p27 turnover at each time point as compared with their controls (Figure 2a) . The turnover rate of p27 (less than 50% remained after 5 h) was slower in p19-expressing cells (Àtet) than in control cells ( þ tet) (less than 50% remained after 2 h) (Figure 2b ), suggesting that p19 overexpression leads to stabilization of p27. We also found that p27 was accumulated when cells were treated with specific 26S proteasome inhibitor MG132 (Figure 2c ), indicating that the stabilization of p27 protein was due to the activity of p19 in decelerating the ubiquitin-mediated degradation of p27. HER2 signaling is involved in enhancing ubiquitination of p27 (Yang et al., 2000b) . Since the specific E3 ubiquitin ligase involved in p27 degradation is the SCF SKP2 -ROC1 complex, consisting of Skp1, Cul1, ROC1, and a distinct F box protein, Skp2, that acts as a substrate-recognition component to ubiquitinate p27 (Carrano et al., 1999; Sutterluty et al., 1999; Tsvetkov et al., 1999) , we determined whether p19 could inhibit Skp2-mediated p27 ubiquitination in the presence of HER2. Cells were cotransfected with Skp2, pCMV-HER2, pCMV-His-ubiquitin, and increasing amounts of p19. Cells were harvested and analysed by His-Bind resin binding for the presence of His-ubiquitincontaining p27. Skp2 can act as a ubiquitin ligase and will add His-ubiquitin onto its target p27. Thus, the Hisubiquitinated form of p27 can be detected in the His-ubiquitin-containing protein complexes bound to His-Bind resin by immunoblotting with anti-p27. Amounts of His-ubiquitinated form of p27 decreased with increasing p19, suggesting that p19 inhibited Skp2-mediated p27 ubiquitination in the presence of HER2 ( Figure 2d ).
p19ARF regulates the expression of Skp2 and Cul1
Skp2 and Cul1 are two key components of the SCF SKP2 -ROC1 complex that are directly involved in regulating the stability and half-life of p27 through ubiquitinproteasome pathway. Since Skp2 (the F-box protein) and Cul1 are ubiquitinated and degraded (Galan and Peter, 1999; Morimoto et al., 2003) , we evaluated whether p19 regulated the turnover of Skp2 and Cul1. Expression of Skp2 and Cul1 was decreased when overexpression of p19 was induced through tet regulation ( Figure 3a) . Thus, we inferred that high p19 expression leads to decreased stability of Skp2 and Cul1. To test this hypothesis, we determined the protein stability of Skp2 and Cul1 by cycloheximide treatment in NIH3T3/HER2/tTA-p19 cells treated with or without tetracycline. The turnover rate of Skp2 (less than 50% remained after 2 h) and Cul1 (less than 50% remained after 5 h) was faster in p19-expressing cells (Àtet) than in tet-treated cells , suggesting that increasing turnover of Skp2 and Cul1 by p19 overexpression participated in restoring the protein stability of p27.
p19ARF inhibits Akt activity and Akt-mediated p27 phosphorylation
When the amount of p19 was increased, the phosphorylation of Akt substrates decreased (Figure 4a ), suggesting that p19 affected endogenous Akt's kinase activity toward its substrates. Akt can phosphorylate GSK3b (Cross et al., 1995) , threonine 157 of p27 (Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) , and threonine 198 of p27 (Fujita et al., 2002) . Thus, we investigated further the effects of p19 on Akt kinase activity using a kinase assay. NIH3T3/HER2/tTA-p19 cells were treated with different amounts of tetracycline. Akt was immunoprecipitated and assayed for its ability to phosphorylate GSK3b and p27 (Figure 4b ). Aktmediated phosphorylation of GSK3b (Figure 4c ) and Figure 2 p19ARF inhibits Skp2-mediated p27 ubiquitination. (a) p27 stability in NIH3T3/HER2/tTA-p19 cells. NIH3T3/HER2/ tTA-p19 cells were treated with or without tetracycline (tet) and were treated with cycloheximide (CHX) (100 mg/ml) for the indicated time. Cell lysates were immunoblotted with anti-p27. Tubulin served as a loading control. (b) Quantitation of p27 protein level in (a). Levels of p27 were measured using a densitometer. The level of p27 at time 0 was set at 100%. (c) p27 was stabilized in the presence of 26S proteasome inhibitor. NIH3T3/HER2/tTA-p19 cells were treated with the indicated amounts of tetracycline. Cells were then treated with or without the 26S proteasome inhibitor MG132. Equal amounts of cell lysates were immunoblotted with anti-p27. (d) p19 inhibited Skp2-mediated p27 ubiquitination. 293T cells were cotransfected with equal amount of Skp2 (3 mg), pCMV-p27 (1 mg), pCMV-HER2, and pCMV-His-ubiquitin (1 mg ), and increasing amounts of pCMV-p19 (0, 1, 4, and 8 mg). The cell lysates were harvested, and the His-ubiquitin containing protein complexes were pulled down using His-Bind resin (Novagen, Germany). The protein complexes were then resolved on 12% SDS-polyacrylamide gel and probed with anti-p27 antibody to reveal the Hisubiquitinated p27. Equal amounts of cell lysates were immunoblotted with anti-HER2, anti-Skp2 and p19 . Phosphorylated protein bands were measured using a phosphoimager program. The phosphorylated level of GSK3b or p27 at 2 mg/ml of tet was set at 100% p27 ( Figure 4d ) was high in the presence of tetracycline but severely reduced in untreated (p19-expressing) cells (Figure 4c, d) . Together, these data indicated that p19 overexpression inhibited Akt kinase activity in HER2-overexpressing cells. As Akt causes the cytoplasmic localization of some of its substrates, including p27 (Fujita et al., 2002; Viglietto et al., 2002) , we assayed whether p19's inhibitory activity toward Akt in the context of HER2 overexpression modulated Aktmediated p27 subcellular localization. Cells were treated with tetracycline (control) or not treated with tetracycline and subjected to an immunofluorescence detection. Cellular p27 was cytoplasmic in tet-treated control cells (Figure 5a ), confirming HER2's role in regulating p27 localization (Yang et al., 2000b) . Importantly, p27 cytoplasmic localization was dramatically reduced in cells with overexpression of p19 induced through tet regulation (Figure 5a ), suggesting that p19 inhibits the HER2-mediated cytoplasmic localization of p27. Given that HER2 signaling affects the cytoplasmic localization of CSN5 (Jab1) (Yang et al., 2000b) , a p27 exporter involved in p27 degradation, to mediate p27 degradation, it is possible that p19 has an impact on CSN5. However, in our immunofluorescence study, p19 did not affect the localization of CSN5 (Figure 5a ). We evaluated whether CSN5 had any opposing effect on p19 expression, which would compromise p19's effect. In a transient transfection assay, CSN5 had no effect on p19 protein stability, whereas CSN5 mediated the degradation of p27 (Figure 5b ). Taken together, our findings suggest that p19 does not affect p27 stability through regulation of CSN5 even though CSN5 can mediate p27 degradation. It is possible that p19 is only targeting the Akt pathway to affect the subcellular localization and subsequent degradation of p27.
p19ARF inhibits HER2-mediated cell survival and taxol resistance HER2 has been implicated in processes linked to cell survival (Holbro et al., 2003) . For example, cells overexpressing HER2 may activate Akt and are more resistant to apoptosis-inducing agent such as tumor necrosis factor (Zhou et al., 2000) . In addition to inhibiting Akt activity, we found that cells overexpressing p19 through tet regulation showed higher p53 expression, and more p53 upregulated modulator of apoptosis (PUMA) (Nakano and Vousden, 2001; Yu et al., 2001 ) expression than control cells (Figure 6a ), suggesting that p19 can mediate apoptosis in HER2-overexpressing cells. We then determined whether p19 could specifically block the HER2-mediated survival activity using fluorescence-activated cell sorting (FACS) analysis. Overexpression of p19 induced through tet regulation for 2 days resulted in G2 arrest (Figure 6b ), whereas cells induced for 6 days had a higher sub-G1 population (58%) than control cells (4.99%), indicating that the overexpression of p19 can overcome the survival signal of HER2 to induce apoptosis, as evident in the increased number of sub-G1 cells. Taken together, these results show that p19 inhibits Akt activity and induces PUMA expression to mediate apoptosis in HER2-overexpressing cells.
HER2 plays an important role in the chemoresistance of breast cancer cells . Recently, HER2 overexpression has been shown to result in Figure 5 p19ARF inhibits HER2-mediated p27 nuclear export. (a) p19 inhibits HER2-mediated p27 nuclear export in NIH3T3/ HER2/tTA-p19 cells. NIH3T3/HER2/tTA-p19 cells were treated with or without tetracycline (tet). Cells were fixed and stained with anti-p27 to permit detection of the location of p27 or stained with anti-CSN5 antibodies to permit observation of the location of CSN5. Nuclei were stained with DAPI dye. (b) Effect of CSN5 on p19 and p27. 293T cells were transfected with equal amounts of p27 or p19 expression vector and increasing amounts of the Flag-CSN5 expression vector. Equal amounts of protein from cell lysates were immunoblotted with anti-p27, anti-p19, anti-Flag (CSN5), and anti-tubulin. Tubulin served as a loading control resistance to taxol-induced apoptosis (Yu et al., 1998; Tan et al., 2002) . To determine whether the p19 induced apoptosis in HER2-overexpressing cells can overcome the taxol resistance effect mediated by HER2, we determined the apoptosis-inducing effect of taxol in NIH3T3/HER2/tTA-p19 cells treated with or without tetracycline. We measured apoptosis by quantitating DNA fragmentation using ELISA assay. Taxol alone induced little apoptosis at a high dose (1 mM), whereas taxol plus overexpression of p19 induced through Tet regulation resulted in a 2-3-fold increase in DNA fragmentation over that in cells treated with taxol only (Figure 6c ). Moreover, we investigated whether p19 increased the efficiency of apoptosis induction by 2-ME, a new anticancer agent that inhibits superoxide dismutase (SOD) and induces apoptosis in cancer cells (Huang et al., 2000) . 2-ME alone caused apoptosis. Again, overexpression of p19 induced through tet regulation plus the treatment of 2-ME resulted in a 2-3-fold increase in DNA fragmentation over that in cells treated with 2-ME only (Figure 6d ). These results indicated that p19 promoted apoptosis and potentiated the apoptotic effects of taxol and 2-ME in HER2-overexpressing cells.
p19ARF has tumor suppressive activity in HER2-overexpressing cells
Our initial experiments showed that overexpression of p19 can inhibit growth in HER2-overexpressing cells. We next investigated whether p19 overexpression affected HER2-mediated transformation. The HER2 proto-oncogene can induce transformation by enabling cells to grow in soft agar (anchorage-independent growth). Cells were treated with tetracycline (control) or untreated with tetracycline and were subjected to a soft-agar colony formation assay. Overexpression of p19 induced through tet regulation resulted in fewer colonies than control (Figure 7a ), demonstrating that the overexpression of p19 can suppress the in vitro transformation phenotype of HER2-overexpressing cells.
As p19 blocked HER2-induced cell transformation, we next explored p19's effect on HER2-mediated tumorigenicity in vivo. To evaluate the antitumor activity of p19, we performed a tumorigenicity assay in immunodefficient strains of mice using doxycycline (dox, a derivative of tetracycline) induction. Cells were treated with tetracycline (control) or untreated with tetracycline. The cells were then injected subcutaneously into the flanks of nude mice, and tumor formation was Cells were then treated with Taxol or 2-ME at the indicated concentrations. Induced apoptosis was determined by measuring DNA fragmentation using the cell death ELISA kit (Roche). The results were expressed as the value of A405 reading. The absorbance is directly proportional to apoptosis. Bars, s.d. The average of three independent experiments (7s.e.) is shown. ELISA agents only were used as negative controls (NC) ARF inhibits HER2 oncogenic activity and tumor growth Y Zhang et al assayed. Tumor growth was observed in control mice; however, tumor volume was dramatically decreased in mice with overexpression of p19 induced through dox regulation (Figure 7b ), suggesting that p19 inhibits HER2-mediated tumorigenicity. Tumor tissues from the sites of implantation were assessed for p19 levels by immunoblotting. As expected, transduced p19 protein levels were higher in mice not treated with dox (Figure 7c) , suggesting that the expression of p19 is directly involved in inhibiting tumor growth. In addition, consistent with the results of the cell line studies, the expression of PUMA, p53, and p27 also increased when p19 was induced in the tumors (Figure 7c ). These results demonstrate that overexpression of p19 is sufficient to abolish tumorigenicity in cells transformed by HER2.
Discussion
The high frequency of downregulation of ARF in several types of cancer demonstrates that the dysregulation of ARF plays an important role in human tumorigenesis. HER2 also plays a pivotal role in cancer formation, and its oncogenic activity arises from the activation of both proliferative and antiapoptotic signaling. Thus, the HER2 signaling pathway is an important molecular target for cancer therapy. ARF activity is deregulated in HER2-mediated p53 destabilization, but the tumor suppressor role of ARF in HER2-overexpressing cancers remains unclear. In the study reported here, we showed that ARF expression counteracted HER2 oncogenic signaling. This important biological function blocked the HER2-mediated cytoplasmic localization and ubiquitination of p27 to correct mitogenic cell growth and antagonized HER2-mediated cell survival to promote apoptosis. Importantly, the overexpression of ARF inhibited tumorigenicity mediated by HER2 activity in cancer models. The identification of ARF as a tumor suppressor deregulated in the HER2 signaling pathway indicates that strategic overexpression of ARF should prove useful in the treatment of HER2-associated tumors. HER2 signaling regulates a wide variety of signaling pathways involved in cell cycle control and apoptosis, including the p27 (Yang et al., 2000b) , p21 (Zhou et al., 2001a) , cyclin D1 , and Akt-MDM2-p53 pathways (Zhou et al., 2001b) . HER2 disrupts the regulation of MDM2 by ARF (Figure 1a) , thereby causing p53 degradation. In HER2-overexpressing cells, induced expression of ARF blocked HER2-mediated (Figure 2) . Interestingly, overexpression of ARF also antagonized the nuclear export and degradation of p27 ( Figure 5 ). We found that overexpression of ARF caused the downregulation of Cul1 and Skp2, which are involved in the ubiquitination and degradation of p27 (Morimoto et al., 2000; Podust et al., 2000) , providing the explanation for ARF-mediated p27 upregulation (Figure 3 ). Skp2 is a subunit of Skp1-Cul1-F-box (SCF) protein ubiquitin ligase complexes involved in the ubiquitination and subsequent degradation of p27 (Carrano et al., 1999) . Skp2 binds p27 phosphorylated on Thr187 by CDK2 to facilitate the ubiquitination of p27. NEDD8/Rub1 modification of Cul1 enhances the activity of the SCF ubiquitin ligase toward p27 (Morimoto et al., 2000) (Podust et al., 2000) , thus facilitating p27 degradation. How ARF causes the downregulation of Skp2 remains to be characterized. As PTEN expression leads to p27 accumulation through reduction of Skp2 (Di Cristofano et al., 2001; Mamillapalli et al., 2001) , ARF may regulate PTEN to block Skp2-mediated p27 degradation. This is particular interesting because genetic evidence has demonstrated the collaboration between PTEN and ARF in suppressing oncogenic transformation and tumor growth (You et al., 2002) . Alternatively, because Skp2 is downregulated by connexin 43 Zhang et al., 2003) , a gap junction protein and a tumor suppressor, ARF may regulate connexin 43 to block Skp2-mediated p27 degradation in HER2-overexpressing cells. As for Cul1, it is known that Cul1 is transcriptionally regulated by the Myc oncogene (O' Hagan et al., 2000) . Given that Myc is a downstream effector of HER2 signaling (Hynes and Lane, 2001) (Casalini et al., 2001) (Mackay et al., 2003) , ARF may deregulate Myc to block Cul1 expression in HER2-overexpressing cells, thereby stabilizing p27.
Various human tumors, including breast cancer, have a cytoplasmic mislocation of p27 (Liang et al., 2002; Viglietto et al., 2002) (Shin et al., 2002) . We previously showed that HER2 signaling results in cytoplasmic mislocation of p27 (Yang et al., 2000b) . One of the mechanisms responsible for the altered subcellular localization of p27 is mediated by Akt activity. Akt activation correlates with T157 and T198 phosphorylation and the cytosolic mislocation of p27 in breast cancer (Viglietto et al., 2002) (Fujita et al., 2002) . Given that Akt is an important mediator of HER2 signaling, it is possible that HER2 signals activate Akt to regulate p27 localization. We found that ARF expression antagonized the activity of Akt and rescued p27 mislocalization, suggesting that ARF acts as an upstream inhibitor of Akt in the presence of HER2. Genetic evidence has shown that Ink4a-ARF loss collaborates with Ras and Akt to form glioblastoma from astrocytes, suggesting a link between ARF and Akt (Uhrbom et al., 2002) . How ARF inhibits Akt remains to be determined.
ARF has the ability to induce apoptosis by cooperating with p53 (Tango et al., 2002) . This is due to the fact that ARF affects p53 indirectly through modulation of the ARF/MDM2/p53 pathway. On the other hand, ARF is known to induce p53-independent apoptosis (Hemmati et al., 2002) . Here, we showed that ARF antagonized the activity of Akt in the presence of HER2 (Figure 4) . It is known that Akt is involved in inhibiting apoptosis. Given that ARF expression resulted in decreased Akt kinase activity (Figure 4) , ARF may be involved in regulating some of the important proapoptotic signals regulated by Akt. Interestingly, the overexpression of p27 also results in apoptotic death in several cancer cells (Wang et al., 1997) (Katner et al., 2002) . Since ARF promotes the expression of p27, this link may reveal another layer of ARF's ability to facilitate apoptosis, in addition to promoting p53-mediated apoptosis. Importantly, HER2 can confer resistance to apoptosis-inducing stimuli such as taxol (Tan et al., 2002) . Owing to the ability of ARF to induce apoptosis and sensitize cells to chemotherapeutic agents, such as taxol and 2-Me, in a background of HER2 overexpression (Figure 6 ), administration of ARF with other chemotherapeutic drugs should prove useful in the treatment of HER2-overexpresing cancer.
The fact that ARF inhibited HER2-mediated cell growth and induced apoptosis fits with the observation that mammary tumors from MMTV-ErbB2 mice in the ARF( þ /À) background have increased cell proliferation but decreased mammary tumor apoptosis when compared with MMTV-ErbB2 mice in the ARF( þ / þ ) background (D'Amico et al., 2003) . This animal model suggests that ARF and ErbB2 are genetically linked and provides in vivo evidence that ARF indeed plays an important role in ErbB2-mediated mitogenic growth and survival. However, ARF status does not affect the risk of developing mammary tumors (D'Amico et al., 2003) , probably because of the strong tumorigenic activity of ErbB2. However, we found that overexpression of ARF counteracted the HER2-mediated tumorigenicity, suggesting that enough ARF expression was present for efficient tumor suppression in HER2-overexpressing cells.
On the basis of negative regulatory activity of ARF toward Akt and positive regulatory activity of ARF toward p27 in HER2-overexpressing cells, we have presented a model to highlight the effects of ARF in regulating the HER2 signaling (Figure 8 ). Further, we propose that ARF has tumor-suppressive activity in HER2-activated cancer cells. ARF is also known to regulate cell cycle arrest in a p53-independent manner. Only a few other molecular targets have been shown to mediate such events, such as E2F1 (Eymin et al., 2001) and CDC25C (Eymin et al., 2003) . In this study, we found that Akt and p27 were possible molecular targets moderating the p53-independent effects of ARF. Whether these events are p53 independent and occurred only in the context of HER2 overexpression remains to be determined. However, our studies indicated that ARF inhibited the tumorigenicity of HER2-transformed cells, highlighting the tumor suppressive role of ARF. Given that HER2 promotes cell growth and survival and is activated in several types of cancers as a result of dysregulation of Akt or p27 activity, our findings regarding the negative role of ARF in HER2 signaling and the potential of ARF as an anticancer agent have important clinical relevance. Targeting HER2-overexpressing cancer cells by the administration of ARF could be an excellent therapeutic regimen for the treatment of cancers in which the HER2 signaling pathway is constitutively activated, including a high percentage of ovarian and breast cancers.
Materials and methods
Cell culture and reagents
293T, NIH3T3/HER2/tTA-p19 cells were cultured in DMEM medium containing 10% fetal bovine serum. A CaPO4 method was used to transiently transfect 293T cells. NIH3T3/HER2/ tTA-p19 cells were generated from NIH3T3/HER2/tTA cell. NIH3T3/HER2/tTA cell line was generated by transfecting pUHD15-1 (neo) vector (Gossen and Bujard, 1992) into NIH3T3/HER2 cells using the Fugene 6 transfection reagent. At 2 days after transfection, cells were selected in 600 mg/ml G418 media for 2-3 weeks. Positive clones were selected and assayed by transient transfection of pUHC13-3 (tet O/ HCMVIE-luciferase) (Gossen and Bujard, 1992) . p19 was PCR cloned with 5 0 GGACACGCTCATATGGGTCGCAGG TTCTTGGTCACT and 5 0 CATGTAGGATCCCTATGCCC GTCGGTCTGGGCG primers using cDNA from NIH3T3 cells. p19 PCR product was digested with NdeI and BamH1 and cloned into modified pUHD10-3 hygromycin vector to be Flag-tagged and confirmed by sequencing. The plasmid was then introduced into NIH3T3/HER2/tTA cells using Fugene 6 reagent. Hygromycine B (300 mg/ml) plus 2 mg/ml tetracycline was used to select for positive clones over 2-3 weeks. NIH3T3/HER2/tTAp19 cells were cultured in medium without 2 mg/ml tetracycline for induced expression. Tetracycline (sigma), Taxol (Sigma), 2-Mexoyestradiol (Sigma), MG132 (sigma), cycloheximide (Sigma) were used in the indicated experiments. Cells were treated with cycloheximide (100 mg/ml) for the indicated times to assay protein stability.
Western blot analysis
Total cell lysates were solubilized in lysis buffer (20 mM TrisHCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP40, 0.5% Triton X-100, 1 mM PMSF, 1 mM NaF, 1 mM sodium orthovanadate, 1 mg each of aprotinin, leupeptin, and pepstatin/ml) and were processed as previously described (Yang et al., 2000b) . For the immunoprecipitation assay, the cells were lysed and immunoprecipitated with anti-Flag (M2) (Sigma) or anti-MDM2 (anti-MDM2 (H221) (Santa Cruz biotechnology) and immunoblotted with the indicated antibodies. Western analysis was performed on 12% polyacrylamide gels with a 5% polyacrylamide stacking gel. After electrophoretic transfer (Amersham Pharmacia) of protein from SDS-polyacrylamide gels to PVDF membranes (Millipore), the membranes were blocked with buffer containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20, 5% of blotto (Bio-Rad) for 1 h at room temperature and incubated 1h at room temperature with primary antibodies: anti-Flag (M2)(Sigma), anti-p27 (Zymed Laboratories Inc), anti-p53 (FL-393) (Santa Cruz Biotechnology), anti-PUMA (ProSci), anti-tubulin (Sigma), anti-cullin-1( Cul1) (NeoMarkers), anti-CSN5 (GeneTex), anti-Skp2 (Zymed Laboratories), antiCyclin D1 (NeoMarkers), anti-C-neu (Ab-3, HER 2, Calbiochem), anti-p19 ARF (G-19, Santa Cruz Biotechnology), anti-HA (Upstate biotechnology), anti-Akt (Cell signaling), antiphospho-(Ser/Thr) Akt Substrate (Cell signaling), anti-phospho-Akt (Ser473) (Cell signaling), (anti-MDM2 (H221) (Santa Cruz biotechnology). Subsequently, membranes were washed and incubated half an hour at room temperature with peroxidase-conjugated secondary antibodies. Following several washes, membranes were incubated with chemiluminescence (ECL) system (Roche Molecular Biochemicals), according to the manufacturer's instructions.
Luciferase reporter gene assay
The cyclin D1-luciferase reporter (À1745CD1LUC , a gift from Dr Richard Pestell,) was cotransfected with pCMV-HER2 or pCMV-p19 expression vectors into 293T cells. Luciferase activity was assayed using the Dual Luciferase Assay system (Promega) according to the manufacturer's instructions.
Kinase assays
NIH3T3/HER2/tTA-p19 cells were treated with the indicated amounts of tetracycline. Cell lysates were immunoprecipitated with anti-Akt or anti-CDK2. Immune complexes were incubated with 0.04 mg of GSK3b (Cell Signaling) or 1 mg of Flag-p27 (bacterially produced by using the expression vector pET21a (Novagene) and purified as previously described (Lee et al., 1995) or 50 mg/ml histone H1 with 10 mCi [g-32 P]ATP (Amersham) for a kinase assay as previously described (Yang et al., 2001) . Phosphorylated substrate was visualized using a STORM840 PhosphorImager.
Ubiquitination assay
The 293T cells were cotransfected with pCMV-Skp2 (3 mg), pCMV-HER2 (1 mg ), His-ubiquitin (1 mg), and increasing amount of FLAG-p19. After 24 h post-transfection, cells were treated with 200 mM ALLN (N-acetyl-Leu-Leu-norleu-AL, Sigma) for 12 h. The cell lysates were harvested with lysis buffer (50 mM Tris, pH 7.5, 150 mm NaCl, 0.5% NP40, 0.5%Triton-100, and 5mM NEM). The His-ubiquitin containing protein complexes were pulled down using His-Bind resin (Novagen, Germany). The protein complexes were then resolved on 12% SDS-polyacrylamide gel and probed with anti-p27 to observe the ubiquitinated p27. Apoptosis assay NIH3T3/HER2/tTA-p19 cells were treated with 2 mg/ml tetracycline or without tetracycline. Cells were then treated with apoptosis-inducing agents (Taxol or 2-ME). Floating and attached cells were harvested 16 h after the treatment. Cells were lysed at room temperature for 30 min, and dilutions of these extracts were used for cell-death ELISA, which was performed according to the manufacturer's protocol (Roche).
Immunofluorescence assay NIH3T3/HER2/tTA-p19 cells were treated with 2 mg/ml tetracycline or without tetracycline. Cells were prepared and seeded onto chamber slides with 2 Â 10 5 cells/well 1 day prior to staining. Cells were then fixed with methanol/acetone (1 : 1 v/v) at RT for 2 min and stained for 1 h with rabbit anti-p27 followed by 1 h incubation with Cy3-conjugated anti-rabbit antibody (Zymed). Mouse CSN5 antibody anti-CSN5 (GeneTex) was used and followed by Texas red-conjugated antimouse antibody (Jackson Research Laboratories) to stain the localization of CSN5. For all staining, the cells were incubated with 0.1 mg/ml of 4,6-diamidino-2-phenylindole (DAPI) (Sigma) to stain the nuclei. Immunofluorescence was detected using an Axioplan 2 fluorescence microscope (Zeiss).
MTT assay, FACS assay, and soft-agar colony formation assay NIH3T3/HER2/tTA-p19 cells were treated with 2 mg/ml tetracycline or without tetracycline and were subjected to these assays. These assays were performed as described (Yang et al., 2001) .
Tumor growth in nude mice
Female 4-5-week-old nude mice (Charles River Laboratories) were maintained in the animal facility at the University of Texas M.D. Anderson Cancer Center. Mice were divided into two experimental groups, with six mice in each group. NIH3T3/HER2/tTA-p19 cells (1 Â 10 6 cells in 0.2 ml PBS per injection with 2 mg/ml tet for one group, and without tet for the other) were injected subcutaneously into the flanks of mice, and each mouse was inoculated with cells at two sites. After cell inoculation, animals were fed with drinking water containing 5% sucrose in the presence or absence of 200 mg/ ml doxycycline (Sigma) (Kistner et al., 1996) . Drinking water was changed every other day for a 2-week period of tumor formation. Tumor volumes were measured and recorded everyday. At the end of 2 weeks, the mice were killed, and the tumors were removed for detection of p19, PUMA, p53, and p27.
